Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
48
EVOK Quote, Financials, Valuation and Earnings
Last price:
$4.89
Seasonality move
:
1.96%
Day range:
$4.80 - $5.03
52-week range:
$3.54 - $14.04
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.55x
P/B ratio:
1.68x
Volume:
15.5K
Avg. volume:
48K
1-year change:
-64.06%
Market cap:
$7.4M
Revenue:
$5.2M
EPS (TTM):
-$11.03
Analysts' Opinion
-
Consensus RatingEvoke Pharma has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Evoke Pharma has an estimated upside of 262.9% from its current price of $4.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $4.96.
Fair Value
-
According to the consensus of 0 analysts, Evoke Pharma has 262.9% upside to fair value with a price target of -- per share.
EVOK vs. S&P 500
-
Over the past 5 trading days, Evoke Pharma has overperformed the S&P 500 by 6.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Evoke Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evoke Pharma has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Evoke Pharma reported revenues of $2.7M.
Earnings Growth
-
Evoke Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Evoke Pharma reported earnings per share of -$0.94.
Enterprise value:
1M
EV / Invested capital:
0.11x
Price / LTM sales:
0.55x
EV / EBIT:
--
EV / Revenue:
0.12x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.3M
Return On Assets:
-57.27%
Net Income Margin (TTM):
-71.33%
Return On Equity:
-433.12%
Return On Invested Capital:
-95.76%
Operating Margin:
-48.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.1M | $4.3M | $8.6M | $1.6M | $2.7M | |
| Gross Profit | $1.8M | $4M | $8.3M | $1.5M | $2.6M | |
| Operating Income | -$7.6M | -$7.3M | -$5.9M | -$1.6M | -$1.3M | |
| EBITDA | -$7.6M | -$7.1M | -$5.6M | -$1.6M | -$1.2M | |
| Diluted EPS | -$32.64 | -$27.19 | -$11.03 | -$6.08 | -$0.94 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.7M | $11.6M | $13.3M | $7.8M | $14M | |
| Total Assets | $6.8M | $11.6M | $13.4M | $7.9M | $14.2M | |
| Current Liabilities | $6.6M | $1.4M | $1.9M | $2.2M | $9.8M | |
| Total Liabilities | $8.7M | $6.9M | $7.9M | $8.7M | $9.8M | |
| Total Equity | -$1.9M | $4.8M | $5.5M | -$873.8K | $4.4M | |
| Total Debt | -- | $5M | $5M | $5M | $5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.1M | -$6.4M | -$5.3M | -$1M | -$818.7K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $7.3M | -- | $10.7M | -- | $3M | |
| Free Cash Flow | -$6.1M | -$6.4M | -$5.3M | -$1M | -$818.7K | |
EVOK
Sector
Market Cap
$7.4M
$45.6M
Price % of 52-Week High
35.33%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-157.73%
-0.74%
1-Year Price Total Return
-64.06%
-31.35%
Beta (5-Year)
0.162
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$4.78
200-day SMA
Sell
Level
$5.58
Bollinger Bands (100)
Buy
Level
4.26 - 5.54
Chaikin Money Flow
Sell
Level
-416.2M
20-day SMA
Buy
Level
$4.47
Relative Strength Index (RSI14)
Buy
Level
54.79
ADX Line
Buy
Level
19.79
Williams %R
Neutral
Level
-45.6647
50-day SMA
Sell
Level
$4.97
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
342.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-27.3806)
Sell
CA Score
(Annual)
Level (-5.6558)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (12.0409)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Stock Forecast FAQ
In the current month, EVOK has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EVOK average analyst price target in the past 3 months is --.
-
Where Will Evoke Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evoke Pharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Evoke Pharma?
Analysts are divided on their view about Evoke Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evoke Pharma is a Sell and believe this share price will drop from its current level to --.
-
What Is Evoke Pharma's Price Target?
The price target for Evoke Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EVOK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evoke Pharma is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of EVOK?
You can purchase shares of Evoke Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evoke Pharma shares.
-
What Is The Evoke Pharma Share Price Today?
Evoke Pharma was last trading at $4.89 per share. This represents the most recent stock quote for Evoke Pharma. Yesterday, Evoke Pharma closed at $4.96 per share.
-
How To Buy Evoke Pharma Stock Online?
In order to purchase Evoke Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
